June 24, 2011

Sanofi Announces Positive Results from the “All to Target” Study Evaluating Two Lantus® and Apidra® Regimens versus Premixed Regimen

- Data Presented at American Diabetes Association’s 71st Annual Scientific Sessions -

 

Sanofi Announces Positive Results from the “All to Target” Study Evaluating Two Lantus® and Apidra® Regimens versus Premixed Regimen
- Data Presented at American Diabetes Association’s 71st Annual Scientific Sessions -

Paris, France – June 24, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from a 60-week, open-label study that compared three intensified insulin regimens added to oral therapy for uncontrolled type 2 diabetes and found that using two regimens including Lantus® (insulin glargine [rDNA origin] injection) and Apidra® (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycemia and improvement in diabetes-specific quality of life.